Merit Medical Systems (MMSI) AGM 2026 summary

Opening remarks and agenda

• Expressed appreciation for employees and stakeholders, highlighting a unique and successful year with record revenue and strong operating results.

• Announced the completion of the second year of the Continued Growth Initiatives Program, emphasizing profitability and innovation.

• Introduced the agenda, including five business items for shareholder voting and outlined the meeting's structure.

Financial performance review

• Achieved record revenue, strong free cash flow, and operating results at the upper end of the peer group for 2025.

• Continued innovation across the portfolio, including milestones for SCOUT and new product launches such as Prelude Wave and Ventrax Delivery System.

• Acquisition of Biolife and C2 CryoBalloon expanded the endoscopy platform.

Board and executive committee updates

• Leadership transition with Martha Aronson appointed as President and CEO.

• Welcomed new director Scott Ward and recognized the re-election of Martha Aronson, Lonny Carpenter, and Lynne Ward.

• Expressed gratitude to outgoing directors David Floyd and founder Fred Lampropoulos for their significant contributions.